HRP20220234T1 - Kristalni oblici - Google Patents

Kristalni oblici Download PDF

Info

Publication number
HRP20220234T1
HRP20220234T1 HRP20220234TT HRP20220234T HRP20220234T1 HR P20220234 T1 HRP20220234 T1 HR P20220234T1 HR P20220234T T HRP20220234T T HR P20220234TT HR P20220234 T HRP20220234 T HR P20220234T HR P20220234 T1 HRP20220234 T1 HR P20220234T1
Authority
HR
Croatia
Prior art keywords
4carbonyl
phosphono
pyrrolidin
propionyl
piperazine
Prior art date
Application number
HRP20220234TT
Other languages
English (en)
Croatian (hr)
Inventor
Daniel Leuenberger
Stefan Reber
Markus Von Raumer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of HRP20220234T1 publication Critical patent/HRP20220234T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20220234TT 2016-09-22 2017-09-21 Kristalni oblici HRP20220234T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
EP17771436.7A EP3515924B1 (en) 2016-09-22 2017-09-21 Crystalline forms
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (1)

Publication Number Publication Date
HRP20220234T1 true HRP20220234T1 (hr) 2022-05-13

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220234TT HRP20220234T1 (hr) 2016-09-22 2017-09-21 Kristalni oblici

Country Status (27)

Country Link
US (4) US10730896B2 (cg-RX-API-DMAC7.html)
EP (2) EP3981774A1 (cg-RX-API-DMAC7.html)
JP (1) JP7097369B2 (cg-RX-API-DMAC7.html)
KR (1) KR102552795B1 (cg-RX-API-DMAC7.html)
CN (1) CN109715639B (cg-RX-API-DMAC7.html)
AU (1) AU2017331930B2 (cg-RX-API-DMAC7.html)
CA (1) CA3037794A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019000728A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125052T1 (cg-RX-API-DMAC7.html)
DK (1) DK3515924T3 (cg-RX-API-DMAC7.html)
EA (1) EA201990723A1 (cg-RX-API-DMAC7.html)
ES (1) ES2908572T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220234T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057772T2 (cg-RX-API-DMAC7.html)
IL (1) IL265445B2 (cg-RX-API-DMAC7.html)
LT (1) LT3515924T (cg-RX-API-DMAC7.html)
MA (1) MA46266B1 (cg-RX-API-DMAC7.html)
MX (1) MX381590B (cg-RX-API-DMAC7.html)
MY (1) MY193080A (cg-RX-API-DMAC7.html)
PH (1) PH12019500567B1 (cg-RX-API-DMAC7.html)
PL (1) PL3515924T3 (cg-RX-API-DMAC7.html)
PT (1) PT3515924T (cg-RX-API-DMAC7.html)
RS (1) RS62946B1 (cg-RX-API-DMAC7.html)
SI (1) SI3515924T1 (cg-RX-API-DMAC7.html)
TW (1) TWI752086B (cg-RX-API-DMAC7.html)
UA (1) UA124073C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018055016A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017331930B2 (en) 2016-09-22 2021-07-15 Viatris Asia Pacific Pte. Ltd. Crystalline forms
MX393334B (es) 2017-03-15 2025-03-24 Idorsia Pharmaceuticals Ltd Administración subcutánea de un antagonista del receptor p2y12.
WO2022013276A1 (en) 2020-07-15 2022-01-20 Idorsia Pharmaceuticals Ltd Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist
US20240317784A1 (en) 2021-07-13 2024-09-26 Viatris Asia Pacific Pte. Ltd. Process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
OA12970A (en) 2002-12-11 2006-10-13 Schering Ag 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists.
PL1611144T3 (pl) 2003-04-09 2011-03-31 Wyeth Llc Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
BRPI0617636A2 (pt) 2005-10-21 2012-04-17 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
BRPI0810462A2 (pt) 2007-04-23 2014-10-14 Sanofi Aventis Derivados de quinolina-carboxamida como antagonistas de p2y12
EP2225253B1 (en) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
WO2009080227A2 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
CN102369197B (zh) 2009-04-08 2013-11-06 埃科特莱茵药品有限公司 作为adp受体拮抗剂的6-(3-氮杂-二环[3.1.0]己-3-基)-2-苯基-嘧啶
AU2010240527A1 (en) 2009-04-22 2011-12-01 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as P2Y12 receptor antagonists
AU2017331930B2 (en) 2016-09-22 2021-07-15 Viatris Asia Pacific Pte. Ltd. Crystalline forms
MX393334B (es) 2017-03-15 2025-03-24 Idorsia Pharmaceuticals Ltd Administración subcutánea de un antagonista del receptor p2y12.
WO2022013276A1 (en) 2020-07-15 2022-01-20 Idorsia Pharmaceuticals Ltd Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist

Also Published As

Publication number Publication date
TW201813965A (zh) 2018-04-16
WO2018055016A1 (en) 2018-03-29
MY193080A (en) 2022-09-26
EP3515924B1 (en) 2021-12-15
IL265445B2 (en) 2024-05-01
US20200017534A1 (en) 2020-01-16
MX381590B (es) 2025-03-12
US20220275011A1 (en) 2022-09-01
CA3037794A1 (en) 2018-03-29
SI3515924T1 (sl) 2022-04-29
US20250163086A1 (en) 2025-05-22
PH12019500567B1 (en) 2024-01-31
HUE057772T2 (hu) 2022-06-28
IL265445A (en) 2019-05-30
PT3515924T (pt) 2022-03-11
JP2019529553A (ja) 2019-10-17
LT3515924T (lt) 2022-03-10
KR20190052704A (ko) 2019-05-16
MX2019003093A (es) 2019-07-18
AU2017331930B2 (en) 2021-07-15
PH12019500567A1 (en) 2019-11-18
RS62946B1 (sr) 2022-03-31
TWI752086B (zh) 2022-01-11
PL3515924T3 (pl) 2022-04-11
NZ750772A (en) 2023-10-27
US11365209B2 (en) 2022-06-21
US20210009614A1 (en) 2021-01-14
CY1125052T1 (el) 2024-02-16
EA201990723A1 (ru) 2019-10-31
US10730896B2 (en) 2020-08-04
ES2908572T3 (es) 2022-05-03
AU2017331930A1 (en) 2019-03-07
UA124073C2 (uk) 2021-07-14
KR102552795B1 (ko) 2023-07-06
EP3981774A1 (en) 2022-04-13
MA46266B1 (fr) 2022-02-28
BR112019004845A2 (pt) 2019-06-04
CN109715639A (zh) 2019-05-03
IL265445B1 (en) 2024-01-01
JP7097369B2 (ja) 2022-07-07
CN109715639B (zh) 2022-04-19
DK3515924T3 (da) 2022-03-21
MA46266A (fr) 2019-07-31
EP3515924A1 (en) 2019-07-31
US12227532B2 (en) 2025-02-18
CL2019000728A1 (es) 2019-07-05

Similar Documents

Publication Publication Date Title
AR128483A2 (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos
HRP20220234T1 (hr) Kristalni oblici
HRP20160813T1 (hr) Natrijeve i kalcijeve soli derivata dihidrokinazolina i njihova upotreba kao antivirusna sredstva
HRP20250459T1 (hr) Čvrsti oblici i kombinacijski pripravci koji sadrže inhibitor beta-laktamaze i njihove uporabe
HRP20240026T1 (hr) Kruti oblik ribociklib sukcinata
HRP20191525T1 (hr) Inhibitori replikacije virusa influence
JP2018520205A5 (cg-RX-API-DMAC7.html)
HRP20201343T1 (hr) Kristalni oblici 5-kloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidin-2,4-diamina
FI4293009T3 (fi) Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi
HRP20241280T1 (hr) Kruti oblici rukapariba i soli rukapariba
HRP20160886T1 (hr) Besilatna i tosilatna sol derivata dihidrokinazolina i njihova upotreba kao protuvirusna sredstva
HRP20210551T1 (hr) Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
HRP20201470T1 (hr) Oblici soli nilotiniba u krutom stanju
JP2019529553A5 (cg-RX-API-DMAC7.html)
HRP20250660T1 (hr) Čvrsti oblici ixazomib citrata
JP2016539112A5 (cg-RX-API-DMAC7.html)
MX381611B (es) Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, método para prepararlos y composición farmacéutica que los contiene.
CN103819379A (zh) 维生素d3的胆甾烷醇共结晶及其制备方法和应用
HRP20211524T1 (hr) Sol derivata cefalosporina, kristalni kruti oblik istog i postupak za njegovu proizvodnju
MX358669B (es) Croman-6-iloxi-cicloalcanos sustituidos y su uso como productos farmaceuticos.
HRP20251324T1 (hr) Oblici soli rukapariba u krutom stanju
WO2017029642A3 (en) Novel polymorphs of dolutegravir and salts thereof
WO2015000555A3 (en) A novel process for the preparation of tetralin and naphthalene derivatives
ECSP14013309A (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos